Relevance. Trastuzumab is the drug of choice for the HER2+ breast cancer treatment. To determine the trastuzumab pharmacodynamics in personalized therapy a validated bioanalytical method for measuring the concentration of the drug in biological fluids is required. The aim: creation and assessment of the suitability (validation) of a test system based on enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of trastuzumab concentration in human serum/plasma. Materials and methods. The presented test system is a classic ELISA kit with a 96-well polystyrene plate, the wells of which are coated with monoclonal antibodies specific to trastuzumab, secondary goat antibodies to the Fc fragment conjugated with horseradish peroxidase (HRP), substrate solution — (3,5,3',5')-tetramethylbenzidine (TMB) and stop solution. Quality control solutions were prepared by diluting known concentrations of trastuzumab in blank serum. Results. In the course of the work the limit of detection (0.84 ng/ml) and the lower limit of quantitative determination (1.41 ng/ml) of trastuzumab in serum/plasma were established and the high selectivity of analyte determination in a multicomponent matrix was proved. The found average values of trastuzumab concentrations did not deviate from the nominal values by more than 14 % in the entire range of determined concentrations, the intraand interseries precision of the test system did not exceed 8%, and the total method error was 20.1 %. The demonstrated dilution linearity allows the assay to be used to analyze a wide range of trastuzumab concentrations in biological samples. The stability of the components of the test system is defined as at least 1 year under storage conditions. Conclusion. The presented ELISA test system complies with international validation requirements and it is suitable for practical use.
5 June 2019 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
An integral part of preclinical pharmacokinetic studies is the development of a bioanalytical method for determination of the drug in a biological fluid.The aim of the research was to assess the suitability of the test system based on enzyme-linked immunosorbent assay (ELISA) for quantitative determination of rituximab in the blood serum of laboratory animals after intravenous administration of rituximab at a dose corresponding to the therapeutic dose in humans. Th test system was developed by the Scientific and Production Center Probiotech.Materials and methods: the determination of rituximab in biological samples was carried out using a two-stage sandwich-type ELISA, followed by detection based on horseradish peroxidase. The ELISA results were recorded using a microplate photometer at a wavelength of 450 nm.Results: the experiments helped to establish the detection limit (0.24 ng/mL) and the lower limit of quantitation (1.00 ng/mL) of rituximab in rabbit blood serum, they also demonstrated high selectivity of analyte determination in a multicomponent biological matrix. The mean rituximab concentration was within 14 % of the nominal value in the entire working range of the method. The within-run and between-run precision of the assay did not exceed 7.4 %, the total error of the method did not exceed 20.1 %. The linearity of dilution makes it possible to use the assay for the analysis of biological samples with a wide range of rituximab concentrations. The stability of the analyte in the rabbit blood serum was confirmed by storing samples for 6 hours at room temperature, for 50 days at —35 °C, and after 3 freeze-thaw cycles. The validated immunoassay was successfully used to determine the rituximab concentration in biological samples obtained in the rituximab pharmacokinetic trial in rabbits. The accuracy of the results was confirmed for the entire range of the determined concentrations; parallelism was demonstrated between the calibration curve and the results of analysis of serially diluted rabbit serum samples with the maximum concentration of rituximab.Conclusions: the proposed enzyme immunoassay test system can be used for quantitative determination of rituximab in the blood serum of laboratory animals, as it meets acceptance criteria for all validation parameters described in the international guidelines on validation of bioanalytical methods.
1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка терапевтической эффективности, безопасности и переносимости препарата Аленталь крем для наружного применения (АО «ВЕРТЕКС», Россия) по сравнению с оригинальным препаратом — Аэртал крем для наружного применения (ОАО «Гедеон Рихтер», Венгрия) при локальной терапии острого ноцицептивного болевого синдрома у пациентов, перенесших травматическое поражение голеностопного сустава. МАТЕРИАЛ И МЕТОДЫ В исследование был включен 131 пациент, перенесший травму мягких тканей области голеностопного сустава. Больные 1-й группы получали Аленталь крем, 2-й группы — Аэртал крем. Длительность терапии составила 7 дней. Эффективность препаратов оценивалась во время лечения на основании динамики интенсивности болевого синдрома и других симптомов травмы, а также оценки результатов лечения врачом и пациентом. Анализ безопасности включал регистрацию нежелательных явлений по данным клинико-лабораторных исследований. РЕЗУЛЬТАТЫ Аленталь крем по показателям терапевтической эффективности оказался эквивалентен оригинальному препарату Аэртал крем. Анализ оценки динамики клинико-лабораторных показателей, безопасности лечения, включая частоту нежелательных явлений, не выявил достоверных различий между двумя препаратами. ЗАКЛЮЧЕНИЕ Аленталь крем может быть использован в качестве средства для локальной терапии острого ноцицептивного болевого синдрома при травматических повреждениях мягких тканей.
Direkord is an original drug containing the active substance of dicholine succinate, which improves the sensitivity of insulin receptors in neurons to insulin. The aim of this work was to evaluate the efficacy and safety of the drug in ischemic stroke patients in the early recovery period. In total, 160 patients after the first ischemic stroke in the carotid system, confirmed by computed or magnetic resonance imaging, with a stroke duration from 3 weeks to 2 months, mean age 63.2±8.4 years, were randomized into two treatment groups. The first group (n=80) received Direkord intramuscularly at a dose of 600 mg/day for two weeks; the second group (n=80) received a placebo. Treatment response was defined as an improvement in neurological status, functional status, and cognitive function of the patients: at least a two-fold decrease in the total NIHSS score, the total Barthel score ≥ 95, and the total MoCA score ≥ 26. The analysis of the primary endpoint of the study using exact Fisher’s test showed that Direkord was statistically significantly superior to the placebo (p=0.017) in the number of patients who responded to the therapy — 23.7 and 8.7% of patients in groups, respectively. The secondary end point analysis revealed a statistically significant superiority of Direkord over the placebo in reducing neurological deficits on the NIHSS scale (p=0.004), on the Rankin scale (p=0.0357), and on the CGI-I (p<0.001) and PGI-I (p<0.001) global clinical impression scales. Direkord has a good safety profile; thus, no statistically significant differences were found with the placebo in any of the safety parameters, including the number of adverse events, vital signs, laboratory parameters, and ECG. Overall, Direkord is statistically significantly more effective than placebo in recovering function and daily activities after ischemic stroke.
Direkord is an original drug containing the active substance of dicholine succinate, which improves the sensitivity of insulin receptors in neurons to insulin. The aim of the work was to select an optimal dosage and to study the efficacy, safety, and tolerability of Direkord, a solution for intramuscular injection, in ischemic stroke patients in the early recovery period. In total, 132 patients after the first ischemic stroke in the carotid system, confirmed by computed or magnetic resonance imaging, with the stroke remoteness from 3 weeks to 2 months and the mean age of 64.35±8.03 years, were randomized into three treatment groups. Patients in the first (n=44) and second (n=44) groups received Direkord intramuscularly for two weeks at a dose of 400 mg/day and 600 mg/day, respectively. Patients in the third group received placebo. The treatment response was assessed in terms of improved neurological status, functional state, and cognitive functions, including at least a two-fold decrease in the total score on the NIHSS scale, the total score on the Barthel scale ≥95, and the total score on the MoCA scale ≥26. Four weeks after the onset of the study, 34.1, 43.2, and 18.2% of the patients responded to therapy in the first, second, and third group, respectively. An analysis based on the Fisher’s exact test revealed a statistically significant difference between the groups (p=0.036). These results suggest that Direkord is statistically and clinically significantly superior to placebo at a two-week intramuscular therapy at a dose of 600 mg/day in patients with ischemic carotid stroke in the early recovery period. The safety profile of Direkord when used in various therapy regimens does not differ from that of placebo. The phase III study should confirm the preliminary results obtained in the current work.